Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning

被引:48
|
作者
Cheng, Jun [1 ,2 ,3 ]
Pan, Yi [4 ]
Huang, Wei [4 ]
Huang, Kun [5 ,6 ]
Cui, Yanhai [7 ]
Hong, Wenhui [1 ]
Wang, Lingling [1 ]
Ni, Dong [1 ,2 ,3 ]
Tan, Peixin [4 ]
机构
[1] Shenzhen Univ, Hlth Sci Ctr, Sch Biomed Engn, Natl Reg Key Technol Engn Lab Med Ultrasound,Guan, Shenzhen, Peoples R China
[2] Shenzhen Univ, Med Ultrasound Image Comp MUSIC Lab, Shenzhen, Peoples R China
[3] Shenzhen Univ, Marshall Lab Biomed Engn, Shenzhen, Peoples R China
[4] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China
[5] Indiana Univ Sch Med, Dept Biostat & Hlth Data Sci, Indianapolis, IN 46202 USA
[6] Regenstrief Inst Hlth Care, Indianapolis, IN USA
[7] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Radiol, Guangzhou, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
CT radiomics; immune checkpoint inhibitor-related pneumonitis; lung cancer; machine learning; radiation pneumonitis; RADIOGRAPHIC PATTERNS; RADIOTHERAPY; CHEMORADIOTHERAPY; CHEMORADIATION; PEMBROLIZUMAB; CHEMOTHERAPY; CONCURRENT; MUTATIONS; RISK;
D O I
10.1002/mp.15451
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Consolidation immunotherapy after completion of chemoradiotherapy has become the standard of care for unresectable locally advanced non-small cell lung cancer and can induce potentially severe and life-threatening adverse events, including both immune checkpoint inhibitor-related pneumonitis (CIP) and radiation pneumonitis (RP), which are very challenging for radiologists to diagnose. Differentiating between CIP and RP has significant implications for clinical management such as the treatments for pneumonitis and the decision to continue or restart immunotherapy. The purpose of this study is to differentiate between CIP and RP by a CT radiomics approach. Methods We retrospectively collected the CT images and clinical information of patients with pneumonitis who received immune checkpoint inhibitor (ICI) only (n = 28), radiotherapy (RT) only (n = 31), and ICI+RT (n = 14). Three kinds of radiomic features (intensity histogram, gray-level co-occurrence matrix [GLCM] based, and bag-of-words [BoW] features) were extracted from CT images, which characterize tissue texture at different scales. Classification models, including logistic regression, random forest, and linear SVM, were first developed and tested in patients who received ICI or RT only with 10-fold cross-validation and further tested in patients who received ICI+RT using clinicians' diagnosis as a reference. Results Using 10-fold cross-validation, the classification models built on the intensity histogram features, GLCM-based features, and BoW features achieved an area under curve (AUC) of 0.765, 0.848, and 0.937, respectively. The best model was then applied to the patients receiving combination treatment, achieving an AUC of 0.896. Conclusions This study demonstrates the promising potential of radiomic analysis of CT images for differentiating between CIP and RP in lung cancer, which could be a useful tool to attribute the cause of pneumonitis in patients who receive both ICI and RT.
引用
收藏
页码:1547 / 1558
页数:12
相关论文
共 50 条
  • [1] Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer
    Wang, M. D. Peiliang
    Li, M. M. Yikun
    Zhao, M. M. Mengyu
    Yu, M. D. Jinming
    Teng, M. D. Feifei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 128
  • [2] Incidence of Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
    Poulose, Vijo
    CHEST, 2022, 161 (03) : E196 - E197
  • [3] Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer
    Cheng, M.
    Lin, R.
    Bai, N.
    Zhang, Y.
    Wang, H.
    Guo, M.
    Duan, X.
    Zheng, J.
    Qiu, Z.
    Zhao, Y.
    CLINICAL RADIOLOGY, 2023, 78 (05) : e377 - e385
  • [4] Incidence of Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Response
    Atchley, William T.
    Rock, Little
    Alvarez, Carolina
    Saxena-Beem, Shruti
    Schwartz, Todd A.
    Ishizawar, Rumey C.
    Patel, Kunal P.
    Rivera, M. Patricia
    CHEST, 2022, 161 (03) : E197 - E197
  • [5] Immune Checkpoint Inhibitor-Related Pneumonitis
    Gomatou, Georgia
    Tzilas, Vasilios
    Kotteas, Elias
    Syrigos, Konstantinos
    Bouros, Demosthenes
    RESPIRATION, 2021, 99 (11) : 932 - 942
  • [6] Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
    Huang, Jie
    Chen, Xueqin
    Xia, Bing
    Ma, Shenglin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [7] The Role of CT-Based Radiomics Nomogram in Differential Diagnosis of Immune Checkpoint Inhibitor-Related Pneumonitis from Radiation Pneumonitis for Patients with ESCC
    Wen, Q.
    Yang, Z.
    Qiu, Q.
    Xing, L.
    Li, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E350 - E351
  • [8] Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
    Shu, Yang
    Xu, Wei
    Su, Rui
    Ran, Pancen
    Liu, Lei
    Zhang, Zhizhao
    Zhao, Jing
    Chao, Zhen
    Fu, Guobin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
    Tan, Peixin
    Huang, Wei
    He, Xinyan
    Lv, Fengquan
    Cui, Yanhai
    Du, Shasha
    JOURNAL OF IMMUNOTHERAPY, 2023, 46 (02) : 64 - 73
  • [10] Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
    Hao, Yuxuan
    Zhang, Xiaoye
    Yu, Li
    FRONTIERS IN ONCOLOGY, 2022, 12